Natural Tripeptide Shows Promise Against Alzheimer's Amyloid Beta Toxicity

The global burden of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is immense, with amyloid beta (Aβ) peptide aggregation and subsequent neurotoxicity recognized as a central pathological hallmark. Current treatments offer limited efficacy, primarily managing symptoms rather than halting disease progression. There is an urgent need for novel therapeutic strategies, especially those derived from natural sources, that can effectively inhibit Aβ aggregation and protect neurons from damage. This study specifically addresses the knowledge gap in identifying natural, non-toxic compounds capable of multifaceted inhibition of Aβ toxicity.

The Tripep-AβI demonstrated significant anti-aggregation properties in vitro, reducing Aβ fibril formation by up to 45% at a concentration of 10 µM compared to untreated controls. In cell culture, Tripep-AβI significantly protected SH-SY5Y cells from Aβ-induced toxicity, improving cell viability by 30% and reducing apoptosis by 25% (p<0.001). > In the in vivo mouse model, Tripep-AβI at 1.0 mg/kg significantly decreased brain Aβ plaque burden by 28% and improved cognitive function, as evidenced by a 2.1-fold increase in memory retention in behavioral tests compared to vehicle-treated mice (p<0.05). Furthermore, the treatment mitigated oxidative stress markers by approximately 20% and reduced neuroinflammation, suggesting a multifaceted mechanism of action beyond just aggregation inhibition. These findings highlight the tripeptide's potential to counteract several aspects of Aβ pathology.